Liso-cel cost-effective for second-line relapsed/refractory lymphoma

Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood Advances.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart